top of page

Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway Trial


COPENHAGEN, Denmark, May 13, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced 2-year results from a post-hoc analysis of the Company’s Phase 3 PaTHway Trial demonstrating significant and sustained improvements in renal function in adults with chronic hypoparathyroidism treated with TransCon PTH (palopegteriparatide). The data were shared in an oral presentation on May 12 by Peter Schwarz, M.D., Professor of Clinical Medicine at the University of Copenhagen, during the European Congress of Endocrinology 2024 (ECE 2024), the annual meeting of the European Society of Endocrinology.


“This unparalleled data showing sustained, clinically meaningful improvements in kidney function in these patients reinforce the potential for TransCon PTH to address concerns about soft-tissue calcifications and decreased kidney function associated with conventional therapy,” said Aimee Shu, M.D., Ascendis Pharma’s Senior Vice President of Clinical Development, Endocrine Medical Sciences.


The post-hoc analysis examined the impact of treatment with TransCon PTH on renal function using estimated glomerular filtration rate (eGFR) through Week 104 (n=76) of PaTHway, a Phase 3 double-blind, placebo-controlled trial of 82 dosed adults with chronic hypoparathyroidism randomized 3:1 (TransCon PTH:placebo; both arms initially co-administered with conventional therapy of active vitamin D and oral calcium), with a 26-week blinded period followed by an ongoing 156-week open-label extension period. Across both treatment arms, TransCon PTH treatment resulted in a mean eGFR increase of 8.9 mL/min/1.73m2 (p<0.0001) from baseline at Week 52, sustained at Week 104 with a mean change from baseline of 9.0 mL/min/1.73m2 (p<0.0001). Treatment was generally well-tolerated, with no new safety signals.

eGFR* Change from Baseline by Study Arm

 

Baseline

Week 26

Week 52

Week 104

Study Arm

eGFR


(mL/min/1.73m2)


N

Mean


(p value)


N

Mean


(p value)


N

Mean


(p value)

TransCon PTH / TransCon PTH




 

eGFR < 60

19

+11.4


(p=0.0002)

19

+11.5


(p=0.0003)

18

+13.4


(p<0.0001)

eGFR ≥ 60

41

+6.3


(p=0.0002)

40

+8.2


(p<0.0001)

40

+6.9


(p<0.0001)

All

60

+7.9


(p<0.0001)

59

+9.3


(p<0.0001)

58

+8.9


(p<0.0001)

Placebo


(first 26 weeks) / TransCon PTH**




 

eGFR < 60

4

+0.05


(p=0.9877)

4

+11.7


(p=0.0018)

4

+15.6


(p=0.0067)

eGFR ≥ 60

15

-2.4


(p=0.3280)

15

+6.5


(p=0.0199)

14

+7.6


(p=0.0121)

All

19

-1.9


(p=0.3468)

19

+7.6


(p=0.0014)

18

+9.4


(p=0.0006)

*eGFR (an assessment of kidney filtering capacity) was calculated by the trial’s central lab using the Modification of Diet in Renal Disease Study Group (MDRD) equation (Levey, Ann Intern Med 2006). An eGFR level <60 mL/min/1.73m2 is considered the threshold for impaired kidney function.


**Patients in the placebo arm switched to TransCon PTH following the Week 26 visit.


TransCon PTH treatment was associated with clinically meaningful increases (≥ 5 mL/min/1.73 m2) in eGFR within 26 weeks that were sustained through Week 104 of PaTHway:

Proportion of Participants (%) with ≥ 5 and ≥ 10 mL/min/1.73 m2 Increases in eGFR from Baseline through Week 104*

eGFR Change from Baseline

All Participants

TransCon PTH / TransCon PTH


(n=61)

Placebo (first 26 weeks) / TransCon PTH**


(n=21)

Week 26

Week 52

Week 104

Week 26

Week 52

Week 104

PTH

PTH

PTH

Placebo

Switch to PTH

Switch to PTH

> 5 mL/min/1.73 m2

57%

64%

61%

24%

52%

62%

> 10 mL/min/1.73 m2

43%

43%

46%

10%

39%

38%

 

eGFR Change from Baseline

Participants with Baseline eGFR < 60 mL/min/1.73 m2

TransCon PTH / TransCon PTH


(n=19)

Placebo (first 26 weeks) / TransCon PTH**


(n=4)

Week 26

Week 52

Week 104

Week 26

Week 52

Week 104

PTH

PTH

PTH

Placebo

Switch to PTH

Switch to PTH

> 5 mL/min/1.73 m2

74%

68%

74%

25%

100%

100%

> 10 mL/min/1.73 m2

47%

42%

53%

0%

75%

75%

*Percentages were calculated based on all participants. Patients who did not have an eGFR assessment at the visit were still included in the denominator.

**Patients in the placebo arm switched to TransCon PTH following the Week 26 visit.


Highlights from this ECE oral presentation will be made available on the Investor & News section of the Ascendis Pharma website at https://investors.ascendispharma.com.


About HypoparathyroidismHypoparathyroidism is an endocrine disease caused by insufficient levels of PTH, the primary regulator of calcium and phosphate balance in the body, acting directly on bone and kidneys and indirectly on the intestines. Individuals with hypoparathyroidism may experience a range of severe and potentially life-threatening short-term and long-term complications, including neuromuscular irritability, renal complications, extra-skeletal calcifications, and cognitive impairment. Post-surgical hypoparathyroidism accounts for the majority of cases (70-80%), while other etiologies include autoimmune and idiopathic causes.


About TransCon PTHTransCon PTH (palopegteriparatide) is a prodrug of parathyroid hormone (PTH 1-34) administered once daily, designed to provide parathyroid hormone levels within the normal physiological range across the 24-hour dosing period. TransCon PTH was granted marketing authorization under the brand name YORVIPATH® by the European Commission (EC) and the European Economic Area (EEA) in November 2023 and the United Kingdom’s Medicines & Healthcare Products Regulatory Agency (MHRA) in Great Britain as a PTH replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism. In the United States, the Food & Drug Administration (FDA) has set a PDUFA target action date of May 14, 2024, to complete their review of Ascendis Pharma’s New Drug Application for TransCon PTH for adults with chronic hypoparathyroidism. TransCon PTH is also in development in Japan through Teijin Ltd. and in China through VISEN Pharmaceuticals.



Comments


bottom of page